Compare MBIN & GHRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MBIN | GHRS |
|---|---|---|
| Founded | 1990 | 2018 |
| Country | United States | Ireland |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.3B | 2.0B |
| IPO Year | 2017 | 2021 |
| Metric | MBIN | GHRS |
|---|---|---|
| Price | $49.51 | $17.49 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 3 | 10 |
| Target Price | ★ $67.00 | $42.44 |
| AVG Volume (30 Days) | 115.6K | ★ 333.3K |
| Earning Date | 10-28-2026 | 11-13-2026 |
| Dividend Yield | ★ 0.88% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 4.79 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $10.52 | N/A |
| Revenue Next Year | $3.15 | N/A |
| P/E Ratio | $10.44 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $30.95 | $12.04 |
| 52 Week High | $56.87 | $31.44 |
| Indicator | MBIN | GHRS |
|---|---|---|
| Relative Strength Index (RSI) | 39.73 | 34.73 |
| Support Level | $47.81 | $14.36 |
| Resistance Level | $51.01 | $22.51 |
| Average True Range (ATR) | 1.40 | 1.29 |
| MACD | -0.36 | 0.00 |
| Stochastic Oscillator | 3.97 | 7.44 |
Merchants Bancorp is a United States-based bank holding company operating multiple lines of business focused on FHA multi-family housing and healthcare facility financing and servicing, retail and correspondent residential mortgage banking, and traditional community banking. Its segments include Multi-family Mortgage Banking, which originates and services government-sponsored mortgages for multi-family and healthcare facilities; Mortgage Warehousing, which offers mortgage warehouse financing, commercial loans and deposit services; and the Banking segment, which generates maximum revenue and provides portfolio lending for multi-family and healthcare facility loans, residential mortgage banking, agricultural lending, SBA lending and community banking.
GH Research PLC is a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients by developing a practice-changing treatment for depression. Its initial focus is on developing novel and proprietary mebufotenin therapies for the treatment of patients with Treatment-Resistant Depression, or TRD. Its portfolio currently includes GH001, a proprietary inhalable mebufotenin product candidate, and GH002, a proprietary intravenous mebufotenin product candidate. The group has only a single segment: Research and Development.